Table 2 Expression of CBP and GCN5 in tissue samples from breast cancer patients with different subtypes by IHC
From: The impact of CBP expression in estrogen receptor-positive breast cancer
Group [58] | CBP expression | GCN5 expression | ||||
|---|---|---|---|---|---|---|
Negative (%)a | Positive (%)b | p valuec | Negative (%)a | Positive (%)b | p valuec | |
Luminal A | 3 (3.5) | 82 (96.5) | 0.0001 | 9 (10.7) | 75 (89.3) | 0.166 |
Luminal B HER2- | 3 (13.0) | 20 (87.0) | Ā | 3 (13.6) | 19 (86.4) | Ā |
Luminal B HER2+ | 0 (0) | 9 (100) | Ā | 1 (11.1) | 8 (88.9) | Ā |
HER2āoverexpressed | 3 (37.5) | 5 (62.5) | Ā | 1 (11.1) | 8 (88.9) | Ā |
Triple negative | 11 (25.6) | 32 (74.4) | Ā | 8 (17.8) | 37 (82.2) | Ā |
Total | 168 | Ā | 169 | Ā | ||
No. of missing data (%) | 41 (19.6) | Ā | 42 (19.9) | Ā | ||